Orion Portfolio Solutions LLC Lowers Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Orion Portfolio Solutions LLC reduced its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTXFree Report) by 23.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 21,754 shares of the company’s stock after selling 6,823 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in SpringWorks Therapeutics were worth $794,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of SpringWorks Therapeutics by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 4,922,462 shares of the company’s stock valued at $113,807,000 after buying an additional 20,651 shares during the period. Mutual of America Capital Management LLC acquired a new stake in shares of SpringWorks Therapeutics in the 4th quarter valued at approximately $2,344,000. Walleye Capital LLC lifted its holdings in shares of SpringWorks Therapeutics by 196.8% in the 3rd quarter. Walleye Capital LLC now owns 144,307 shares of the company’s stock valued at $3,336,000 after buying an additional 95,694 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of SpringWorks Therapeutics by 1.6% in the 4th quarter. New York State Common Retirement Fund now owns 253,741 shares of the company’s stock valued at $9,262,000 after buying an additional 3,987 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of SpringWorks Therapeutics by 16.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,764 shares of the company’s stock valued at $9,797,000 after buying an additional 59,138 shares during the period.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on SpringWorks Therapeutics from $73.00 to $74.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Barclays lifted their price objective on SpringWorks Therapeutics from $47.00 to $63.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Wedbush reaffirmed an “outperform” rating and set a $75.00 price objective (up from $70.00) on shares of SpringWorks Therapeutics in a report on Thursday, May 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a report on Friday, May 31st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, SpringWorks Therapeutics presently has an average rating of “Buy” and a consensus price target of $68.83.

Check Out Our Latest Stock Report on SWTX

SpringWorks Therapeutics Price Performance

NASDAQ SWTX opened at $38.91 on Wednesday. SpringWorks Therapeutics, Inc. has a fifty-two week low of $18.00 and a fifty-two week high of $53.92. The business has a fifty day moving average of $43.95 and a 200-day moving average of $41.96.

SpringWorks Therapeutics (NASDAQ:SWTXGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.01). The business had revenue of $21.00 million for the quarter, compared to the consensus estimate of $12.07 million. The company’s quarterly revenue was up 2000.0% compared to the same quarter last year. During the same quarter last year, the business posted ($1.18) EPS. Sell-side analysts forecast that SpringWorks Therapeutics, Inc. will post -4.6 EPS for the current year.

About SpringWorks Therapeutics

(Free Report)

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.

Recommended Stories

Want to see what other hedge funds are holding SWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SpringWorks Therapeutics, Inc. (NASDAQ:SWTXFree Report).

Institutional Ownership by Quarter for SpringWorks Therapeutics (NASDAQ:SWTX)

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.